Novocure medical assessment is that optune did not contribute to the abscess.The skin in the area of the abscess was intact and the location was not under the array disks.Other contributing factors for abscess/infection in this patient include: chronic steroid therapy, diabetes, underlying cancer disease, prior radiation, chemotherapy and concomitant bevacizumab (vegf inhibitor which carries a black box warning for wound healing complications.Source: bevacizumab prescribing information).There were no reports of abscesses in the (b)(6) trial.There have been 2 reports of abscess in the commercial program to date; neither event was related to optune.
|
Patient with recurrent glioblastoma began optune therapy on (b)(6) 2015.On (b)(6) 2015, during a routine office visit, the prescribing physician noted a small, non-open, tender area on the back of the patient's scalp in the area where the plastic piece of the array wire touched the scalp.Optune was discontinued.The following day, the soreness escalated to serious pain and the area continued to grow.On (b)(6) 2015, patient presented to the emergency room and was admitted to have the abscess drained.Following several attempts of contact with prescriber, no additional information on the hospitalization was provided.At the time of the report, the patient had not restarted optune.Spouse reported that the prescriber had attributed the event to optune, but this was not confirmed by the prescriber.
|